# Philip D. Leming

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/philip-d-leming/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,291 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 22 |
| i10-index | 23 |
| OpenAlex ID | https://openalex.org/A5027983821 |
| ORCID iD | https://orcid.org/0000-0001-5207-3904 |
| Works | 44 |

## Researcher papers

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)
- [Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study](https://scholariq.org/papers/five-year-follow-up-of-nivolumab-in-previously-treated-advanced-non-small-cell/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [vaccines and immunoinformatics approaches](https://scholariq.org/topics/vaccines-and-immunoinformatics-approaches-2/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.